Fidelity Biosciences has injected $65 million into EnVivo Pharmaceuticals Inc. and bought out all other venture investors in the neurological-drug developer.
EnVivo Pharmaceuticals was founded in 2001 and currently has 38 FTEs. EnVivo had raised ~$63.2M in three funding rounds, $14.9M Series A in October 2002 and $24.3M Series B in September 2004, $24M Series C in September 2006. Investors included scientific founders, Fidelity Bioscience Group, BBBC Investor Group that includes Baylor College of Medicine, and CoGene BioTech Ventures.
Fidelity Biosciences Injects $65M, Takes Over EnVivo Pharmaceuticals, Inc.
-(Via BioSpace.com Featured News and Stories.)
Theoretically Related Posts
This post was constructed by .
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)